Found 10 articles for: "upadacitinib"
Clinical Characteristics and Time to Onset of JAK-Inhibitor-Associated Acne: A Retrospective Chart Review Study
August 2026 | Volume 25 | Issue 8 | Original Article | 732 | Copyright © August 2026
Background: Acne is a common cutaneous adverse event associated with Janus kinase (JAK) inhibitors, with incidence varying across agents. Substantial increase in JAK inhibitor us...
Read MoreDual Therapy for Atopic Dermatitis: Lebrikizumab and JAK inhibitors used in Tandem for Treatment-Resistant Cases
June 2026 | Volume 25 | Issue 6 | Features | 569 | Copyright © June 2026
Treatment of Generalized Granuloma Annulare With Biologics and Oral JAK Inhibitors: A Case Series
February 2026 | Volume 25 | Issue 2 | Features | e26 | Copyright © February 2026
Treatment of Refractory Pruritic Dermatitis in the Setting of Primary Biliary Cholangitis and CREST Syndrome With Upadacitinib
November 2025 | Volume 24 | Issue 11 | Case Reports | 1138 | Copyright © November 2025
Primary biliary cholangitis (PBC) can present with overlapping features of limited systemic sclerosis, commonly known as calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, a...
Read MoreThe Role of Simultaneous Janus Kinase Inhibitor and Biologic Therapy Use for Refractory Atopic Dermatitis
October 2025 | Volume 24 | Issue 10 | Case Reports | 1043 | Copyright © October 2025
Treating Chronic Hand Eczema with Upadacitinib: Insights from Clinical Trials and Real-World Experience
July 2025 | Volume 24 | Issue 7 | Features | 702 | Copyright © July 2025
Background: Chronic hand eczema (CHE) is a chronic inflammatory skin condition that affects the hands and wristscausing itching, dryness, cracking, and pain. It ofte...
Read MoreUse of Upadacitinib in Refractory Behcet's Disease: Case Report and Systematic Literature Review
February 2025 | Volume 24 | Issue 2 | Case Reports | e1 | Copyright © February 2025
Oral Lichen Planus Successfully Treated With Upadacitinib
April 2024 | Volume 23 | Issue 4 | Case Reports | e104 | Copyright © April 2024
With the rise of Janus kinase (JAK) and Signal Transducer and Activator of Transcription (STAT) inhibitor use in dermatologic conditions, there has been increasing hope in treating extensive and ...
Read MoreA Case Series of TNF Inhibitor-Induced Psoriasis Successfully Treated With Upadacitinib
February 2024 | Volume 23 | Issue 2 | Case Reports | e60 | Copyright © February 2024
Tumor necrosis factor-alpha inhibitors (TNF-i) are commonly used to treat immune-mediated diseases such as psoriasis, psoriatic arthritis (PsA), inflammatory bowel disease (IBD), spondyloarthriti...
Read MoreSuccessful Treatment of Lichen Planus With Oral Upadacitinib
October 2023 | Volume 22 | Issue 10 | Case Reports | 1058 | Copyright © October 2023
Lichen planus is an auto-inflammatory skin disorder marked by intensely pruritic, violaceous papules that commonly affect the extremities of middle-aged adults.1 There are several trea...
Read More© 2026 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
